ITP study reveals hidden toll on brain and body

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient diagnosed with chronic (ITP with \> 1 year duration) primary ITP living in the USA or the UK: * On ITP pharmacologic treatment, , including on-demand treatment strategy, regardless of last platelet count (below or above 100 x 10\^9 counts/L); * Patients with their most recent platelet count \>50 x 109 counts/L) and without any ITP-specific treatment for 1 year or less. * Adult patient who are 18 years or older at index date * Patient who has received at least one initial first line ITP therapy (CS/ IVIg/ANTI d) with initial response as of index date and indicated by one of the following: * Platelet count ≥ 50 x 10\^9 counts /L; OR * Platelet count ≥ 30 x 10\^9 counts /L with at least a two-fold increase from baseline within 1 month since start of treatment, as per ASH 2019 guidelines; OR * A medical record of initial response as determined by clinical judgement, considering documented platelet count along with overall patient condition and relevant medical factors. * Patients whose medical history related to the study objectives are available from the site covering 12 months prior to index date. * Patient provided informed consent to participate in the study. Exclusion Criteria: * Secondary ITP. * Patients with their most recent platelet count \>50 x 10\^9 counts/L and without any ITP-specific treatment for more than 1 year. * Patients with recent or active infection recorded 14 days or less before index date; patients with uncontrolled chronic infections or who were recently diagnosed with a chronic infection (≤14 days of index date). * Patients with vaccination in 28 days before index date. * Patients treated with rilzabrutinib on or before index date. * Patients who participated in an interventional clinical trial for any investigational drug in the 180 days prior to index date.